Document is current

Article History

Received: 6 March 2025

Accepted: 28 March 2025

First Online: 23 April 2025

Declarations

:

: Sonja Ständer has been a speaker, consultant, investigator, and/or recipient of research funding from Abbvie, Almirall, Beiersdorf, BMS, Clexio, Eli Lilly, FomF, Galderma, Integrity CE, Kiniksa, Leo Pharma, L’Oréal, MEDahead, Moroscience, NACCME, Novartis, Omnicuris, P.G. Unna Academy, Pfizer, Sanofi, TouchIME, UCB, Vifor, and WebMD. Shawn G. Kwatra is an advisory board member/consultant for Abbvie, Aslan Pharmaceuticals, Arcutis Biotherapeutics, Castle Biosciences, Celldex Therapeutics, Galderma, Genzada Pharmaceuticals, Incyte Corporation, Johnson & Johnson, Leo Pharma, Novartis Pharmaceuticals Corporation, Pfizer, Regeneron Pharmaceuticals, and Sanofi and has served as an investigator for Galderma, Incyte, Pfizer, and Sanofi. Dr. Kwatra’s current affiliation is Maryland Itch Center, University of Maryland School of Medicine, Baltimore, MD, USA. Danielle N. Rodriguez, Carla Dias-Barbosa, and Dina Filipenko are employees of Evidera, which was paid by Galderma for work relating to this study. Christophe Piketty, Zarif Jabbar-Lopez, and Jorge Puelles are employees of Galderma, which funded this study. Henning Wiegmann have no conflicts of interest to declare.

: Ethics approval for the qualitative interview study was obtained from Advarra (Columbia, MD; reference number Pro00044847), and participants provided written informed consent before taking part. The OLYMPIA trials were conducted in accordance with the Helsinki Declaration of 1964 and its later amendments, good clinical practice guidelines, and International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use guidelines. Both trials received ethical approval from applicable regulatory authorities and the independent ethics committee or institutional review board at each participating site before study initiation. All participants provided written informed consent.